Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 13Rituximab 11obinutuzumab 6fludarabine phosphate 6Prednisone 6Magnetic Resonance Spectroscopy 6ibrutinib 5fludarabine 5X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Melphalan 5Lenalidomide 5Etoposide 5Doxorubicin 5Biopsy 5tocilizumab 4Whole-Body Irradiation 4venetoclax 3polatuzumab vedotin 3glofitamab 3acalabrutinib 3Vincristine 3Mycophenolic Acid 3Leukapheresis 3Filgrastim 3Cytarabine 3Cyclosporine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × Injections, Subcutaneous × 30 days × Clear all
NCT07603479 2026-05-22

A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Jecho Biopharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
14 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡